Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast density reduction with linzagolix or bilastine in high-risk premenopausal women
2026-525672-26-01Phase 2Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of linzagolix and bilastine in breast cancer (2 arms), sponsored by Parc de Salut Mar. Primary endpoint: Relative percentage change in mammographic breast density. Planned start Oct 2026; status: authorised.
02
Drugs
linzagolixbilastine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-525672-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525672-26-01.